Urogen Pharma (URGN) Downgraded to Market Perform at UBS AG
Urogen Pharma (NASDAQ:URGN) was downgraded by analysts at UBS AG from an “outperform” rating to a “market perform” rating in a report released on Wednesday.
Several other analysts have also recently commented on URGN. Oppenheimer Holdings, Inc. set a $51.00 price target on Urogen Pharma and gave the company a “buy” rating in a report on Tuesday. Zacks Investment Research cut Urogen Pharma from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Finally, Jefferies Group LLC lifted their price target on Urogen Pharma from $27.00 to $37.00 and gave the company a “buy” rating in a report on Monday, October 9th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $33.25.
Shares of Urogen Pharma (URGN) opened at $42.18 on Wednesday. Urogen Pharma has a fifty-two week low of $13.01 and a fifty-two week high of $44.63.
TRADEMARK VIOLATION WARNING: “Urogen Pharma (URGN) Downgraded to Market Perform at UBS AG” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/11/15/urogen-pharma-urgn-downgraded-to-market-perform-at-ubs-ag.html.
Institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC purchased a new stake in Urogen Pharma in the 2nd quarter valued at about $13,892,000. Menora Mivtachim Holdings LTD. grew its holdings in Urogen Pharma by 341.4% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 569,589 shares of the company’s stock valued at $17,953,000 after buying an additional 440,534 shares during the period. DSAM Partners London Ltd purchased a new stake in Urogen Pharma in the 3rd quarter valued at about $2,348,000. Shikiar Asset Management Inc. acquired a new position in shares of Urogen Pharma in the 3rd quarter valued at about $665,000. Finally, Alps Advisors Inc. acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at about $195,000. Institutional investors own 40.55% of the company’s stock.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Stock Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related stocks with our FREE daily email newsletter.